Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graeme Moyle

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
AIDS (London, England)|September 27, 2014
No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individualsGurmit J Singh, Akil Jackson, Antonio D'Avolio, et al.
Lancet (London, England)|August 30, 2008
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE studyJean-Michel Molina, Jaime Andrade-Villanueva, Juan Echevarria, et al.
AIDS (London, England)|March 7, 2025
Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruptionGraeme Moyle, Joshua Gruber, Megan Dunbar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2024
Antiretrovirals and Weight Change: Weighing the EvidenceDavid Alain Wohl, John R Koethe, Paul E Sax, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2010
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionJulian Falutz, Diane Potvin, Jean-Claude Mamputu, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2010
Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjectsGraeme Moyle, Marta Boffito, Albrecht Stoehr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 25, 2009
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE studyJean-Michel Molina, Jaime Andrade-Villanueva, Juan Echevarria, et al.
Plos One|February 14, 2020
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCVSonia Vibhakar Patel, Dushyantha T Jayaweera, Keri N Althoff, et al.
Plos One|June 28, 2016
Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney FibrosisEric Lefebvre, Graeme Moyle, Ran Reshef, et al.
AIDS (London, England)|January 26, 2026
Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/mL and history of K103N mutationGraeme Moyle, Lambert Assoumou, Nathalie De Castro, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
AIDS (London, England)|September 27, 2014
No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individualsGurmit J Singh, Akil Jackson, Antonio D'Avolio, et al.
Lancet (London, England)|August 30, 2008
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE studyJean-Michel Molina, Jaime Andrade-Villanueva, Juan Echevarria, et al.
AIDS (London, England)|March 7, 2025
Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruptionGraeme Moyle, Joshua Gruber, Megan Dunbar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2024
Antiretrovirals and Weight Change: Weighing the EvidenceDavid Alain Wohl, John R Koethe, Paul E Sax, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2010
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionJulian Falutz, Diane Potvin, Jean-Claude Mamputu, et al.
Antimicrobial Agents and Chemotherapy|May 26, 2010
Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjectsGraeme Moyle, Marta Boffito, Albrecht Stoehr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 25, 2009
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE studyJean-Michel Molina, Jaime Andrade-Villanueva, Juan Echevarria, et al.
Plos One|February 14, 2020
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCVSonia Vibhakar Patel, Dushyantha T Jayaweera, Keri N Althoff, et al.
Plos One|June 28, 2016
Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney FibrosisEric Lefebvre, Graeme Moyle, Ran Reshef, et al.
AIDS (London, England)|January 26, 2026
Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/mL and history of K103N mutationGraeme Moyle, Lambert Assoumou, Nathalie De Castro, et al.
Pageof 12